Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 7/2016

01-07-2016 | Letter

The intriguing relationship between epilepsy and type 1 diabetes mellitus

Authors: Josemir W. Sander, Jan Novy, Mark R. Keezer

Published in: Diabetologia | Issue 7/2016

Login to get access

Excerpt

To the Editor: We read with great interest the article by Chou et al reporting a longitudinal cohort study of more than 2500 people with type 1 diabetes mellitus [1]. They were compared with a matched control group in the same administrative database, allowing the investigators to estimate that people with type 1 diabetes were on average 2.8 times more likely to develop epilepsy than those without type 1 diabetes. …
Literature
1.
2.
Keezer MR, Novy J, Sander JW (2015) Type 1 diabetes mellitus in people with pharmacoresistant epilepsy: prevalence and clinical characteristics. Epilepsy Res 115:55–57CrossRefPubMed
3.
McCorry D, Nicolson A, Smith D, Marson A, Feltbower RG, Chadwick DW (2006) An association between type 1 diabetes and idiopathic generalized epilepsy. Ann Neurol 59:204–206CrossRefPubMed
4.
Keezer MR, Sisodiya SM, Sander JW (2016) Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurol 15:106–115CrossRefPubMed
5.
Fisher RS, Acevedo C, Arzimanoglou A et al (2014) ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55:475–482CrossRefPubMed
6.
Kwan P, Sills GJ, Kelly K, Butler E, Brodie MJ (2000) Glutamic acid decarboxylase autoantibodies in controlled and uncontrolled epilepsy: a pilot study. Epilepsy Res 42:191–195CrossRefPubMed
7.
Vincent A, Bien CG, Irani SR, Waters P (2011) Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 10:759–772CrossRefPubMed
8.
Nemni R, Braghi S, Natali-Sora MG et al (1994) Autoantibodies to glutamic acid decarboxylase in palatal myoclonus and epilepsy. Ann Neurol 36:665–667CrossRefPubMed
Metadata
Title
The intriguing relationship between epilepsy and type 1 diabetes mellitus
Authors
Josemir W. Sander
Jan Novy
Mark R. Keezer
Publication date
01-07-2016
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 7/2016
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-016-3982-8

Other articles of this Issue 7/2016

Diabetologia 7/2016 Go to the issue

Review

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

Meta-Analysis

Quantification of the type 2 diabetes risk in women with gestational diabetes: a systematic review and meta-analysis of 95,750 women

Article

Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial

Article

Evaluation of type 2 diabetes genetic risk variants in Chinese adults: findings from 93,000 individuals from the China Kadoorie Biobank

Article

Hypoxia reduces ER-to-Golgi protein trafficking and increases cell death by inhibiting the adaptive unfolded protein response in mouse beta cells

Mini-review

Glucagon action in the brain
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits